Drug Profile
Factors VIII and IX gene therapy - Targeted Genetics
Alternative Names: TgAAV-FVIIILatest Information Update: 14 May 2019
Price :
$50
*
At a glance
- Originator Targeted Genetics
- Developer Targeted Genetics Corporation
- Class
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemophilia A; Haemophilia B
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 18 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Haemotological Disorders and Gene Therapies pharmacodynamics sections
- 03 Mar 2003 Suspended - Preclinical for Haemophilia A in USA (unspecified route)